Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Recently Adopted and Issued Accounting Guidance - Consolidated Statements of Operations (Details)

v3.10.0.1
Recently Adopted and Issued Accounting Guidance - Consolidated Statements of Operations (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Clinical Services $ 59,540 $ 55,547 $ 116,511 $ 108,455
Pharma Services 8,206 6,717 14,658 11,238
Total Revenue 67,746 62,264 131,169 119,693
Gross Profit 30,530 27,352 57,833 50,301
Total operating expenses 29,736 25,511 54,534 49,038
Income from Operations 794 1,841 3,299 1,263
Interest expense 1,407 1,411 2,892 2,775
Income tax (benefit) expense (357) (53) 81 (832)
NET INCOME (LOSS) $ (380) 483 $ 264 (680)
As Reported        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Clinical Services   59,791   116,482
Pharma Services   6,299   11,285
Total Revenue   66,090   127,767
Gross Profit   31,178   58,374
Total operating expenses   29,864   57,175
Income from Operations   1,314   1,199
Interest expense   1,411   2,775
Income tax (benefit) expense   (54)   (879)
NET INCOME (LOSS)   (43)   (697)
Impact of Adoption | Accounting Standards Update 2014-09        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Clinical Services   (4,244)   (8,027)
Pharma Services   418   (47)
Total Revenue   (3,826)   (8,074)
Gross Profit   (3,826)   (8,073)
Total operating expenses   (4,353)   (8,137)
Income from Operations   527   64
Interest expense   0   0
Income tax (benefit) expense   1   47
NET INCOME (LOSS)   $ 526   $ 17